Table 2 |
||||||
|
Associations with lytic/latent KSHV# seropositivity |
||||||
|
Overall KSHV# positive€ |
Positive to Lytic K8.1 only¥ |
Positive to Latent Orf 73 onlyβ |
||||
|
|
||||||
|
Total Positive (n, %) |
Adjusted PR# (95%CI) |
Total Positive (n, %) |
Adjusted PR# (95%CI) |
Total Positive (n, %) |
Adjusted PR# (95%CI) |
|
|
|
||||||
|
Gender |
||||||
|
Female |
127 (66%) |
1 |
104 (66%) |
1 |
73 (62%) |
1 |
|
Male |
66 (34%) |
0.96 (0.77-1.19) |
54 (34%) |
0.98 (0.75-1.26) |
44 (38%) |
1.16 (0.84-1.60) |
|
|
||||||
|
Age category |
||||||
|
< 40 yrs. |
118 (61%) |
1 |
94 (59%) |
1 |
69 (60%) |
1 |
|
≥ 40 yrs. |
75 (39%) |
1.06 (0.86-1.31) |
64 (41%) |
1.00 (0.78-1.29) |
48 (41%) |
0.99 (0.73-1.35) |
|
|
||||||
|
Language |
||||||
|
Zulu |
43 (32%) |
1 |
35 (33%) |
1 |
29 (35%) |
1 |
|
Other |
90 (68%) |
1.21 (0.93-1.58) |
71 (67%) |
1.17 (0.84-1.62) |
54 (65%) |
1.09 (0.75-1.59) |
|
|
||||||
|
Has tuberculosis |
||||||
|
No |
160 (86%) |
1 |
131 (87%) |
1 |
97 (87%) |
1 |
|
Yes |
25 (14%) |
1.06 (0.78-1.42) |
20 (13%) |
1.08 (0.74-1.57) |
15 (13%) |
1.06 (0.67-1.67) |
|
|
||||||
|
BMI category |
||||||
|
< 18.5 |
36 (21%) |
1 |
28 (20%) |
1 |
20 (19%) |
1 |
|
≥ 18.5 |
137 79%) |
1.28 (0.97-1.70) |
114 (80%) |
1.33 (0.94-1.90) |
85 (81%) |
1.46 (0.94-2.26) |
|
|
||||||
|
Hemoglobin |
||||||
|
≥ 8.5 g/dL |
166 (89%) |
1 |
136 (89%) |
1 |
96 (85%) |
1 |
|
< 8.5 g/dL |
21 (11%) |
1.15 (0.84-1.56) |
17 (11%) |
1.17 (0.80-1.72) |
17 (15%) |
1.64 (1.11-2.43) |
|
|
||||||
|
CD4 count |
||||||
|
0-50 cells |
47 (28%) |
1 |
39 (28%) |
1 |
24 (23%) |
1 |
|
51-100 cells |
39 (23%) |
1.18 (0.87-1.62) |
29 (21%) |
1.03 (0.68-1.55) |
28 (27%) |
1.61 (0.97-2.66) |
|
101-200 cells |
65 (38%) |
1.28 (0.97-1.68) |
53 (38%) |
1.16 (0.75-1.81) |
37 (36%) |
1.29 (0.72-2.30) |
|
201-350 cells |
19 (11%) |
0.98 (0.65-1.47) |
17 (12%) |
0.96 (0.52-1.76) |
15 (14%) |
1.27 (0.59-2.90) |
|
|
||||||
|
CD3 count |
||||||
|
< 500 cells |
41 (21%) |
1 |
34 (22%) |
1 |
22 (19%) |
1 |
|
≥ 500 cells |
152 (79%) |
1.35 (1.04-1.76) |
124 (78%) |
1.31 (0.93-1.84) |
95 (81%) |
1.62 (1.04-2.54) |
|
|
||||||
|
CD8 count |
||||||
|
< 500 cells |
64 (33%) |
1 |
54 (34%) |
1 |
35 (30%) |
1 |
|
≥ 500 cells |
129 (67%) |
1.20 (0.96-1.50) |
104 (66%) |
1.09 (0.81-1.47) |
82 (70%) |
1.41 (0.96-2.09) |
|
|
||||||
|
# KSHV = Kaposi sarcoma herpes virus, PR = prevalence ratio estimated from log-binomial regression model. All models adjusted for sex, age and baseline CD4 count € KSHV negative individuals used as the comparison group ¥ Those who did not react to lytic K8.1 including the KSHV negative individuals used as the comparison group β Those who did not react to latent Orf73 including the KSHV negative individuals used as the comparison group |
||||||
|
Maskew et al. Infectious Agents and Cancer 2011 6:22 doi:10.1186/1750-9378-6-22 |
||||||
